rs201392123

Variant summary

Our verdict is Benign. Variant got -16 ACMG points: 0P and 16B. BP6_Very_StrongBS1BS2

The NM_000059.4(BRCA2):​c.8632+132dup variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0017 in 918,952 control chromosomes in the GnomAD database, including 13 homozygotes. Variant has been reported in ClinVar as Benign (★★★).

Frequency

Genomes: 𝑓 0.0069 ( 10 hom., cov: 32)
Exomes 𝑓: 0.00066 ( 3 hom. )

Consequence

BRCA2
NM_000059.4 intron

Scores

Not classified

Clinical Significance

Benign reviewed by expert panel B:5

Conservation

PhyloP100: -0.596
Variant links:
Genes affected
BRCA2 (HGNC:1101): (BRCA2 DNA repair associated) Inherited mutations in BRCA1 and this gene, BRCA2, confer increased lifetime risk of developing breast or ovarian cancer. Both BRCA1 and BRCA2 are involved in maintenance of genome stability, specifically the homologous recombination pathway for double-strand DNA repair. The largest exon in both genes is exon 11, which harbors the most important and frequent mutations in breast cancer patients. The BRCA2 gene was found on chromosome 13q12.3 in human. The BRCA2 protein contains several copies of a 70 aa motif called the BRC motif, and these motifs mediate binding to the RAD51 recombinase which functions in DNA repair. BRCA2 is considered a tumor suppressor gene, as tumors with BRCA2 mutations generally exhibit loss of heterozygosity (LOH) of the wild-type allele. [provided by RefSeq, May 2020]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Benign. Variant got -16 ACMG points.

BP6
Variant 13-32371231-T-TC is Benign according to our data. Variant chr13-32371231-T-TC is described in ClinVar as [Benign]. Clinvar id is 209815.Status of the report is reviewed_by_expert_panel, 3 stars.
BS1
Variant frequency is greater than expected in population afr. gnomad4 allele frequency = 0.00691 (1052/152270) while in subpopulation AFR AF= 0.0242 (1006/41556). AF 95% confidence interval is 0.023. There are 10 homozygotes in gnomad4. There are 488 alleles in male gnomad4 subpopulation. Median coverage is 32. This position pass quality control queck.
BS2
High Homozygotes in GnomAd4 at 10 AD,AR gene

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect #exon/exons MANE UniProt
BRCA2NM_000059.4 linkuse as main transcriptc.8632+132dup intron_variant ENST00000380152.8

Ensembl

Gene Transcript HGVSc HGVSp Effect #exon/exons TSL MANE Appris UniProt
BRCA2ENST00000380152.8 linkuse as main transcriptc.8632+132dup intron_variant 5 NM_000059.4 A2

Frequencies

GnomAD3 genomes
AF:
0.00690
AC:
1050
AN:
152152
Hom.:
9
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.0242
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00216
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00316
Gnomad NFE
AF:
0.0000441
Gnomad OTH
AF:
0.00430
GnomAD4 exome
AF:
0.000661
AC:
507
AN:
766682
Hom.:
3
AF XY:
0.000528
AC XY:
208
AN XY:
393676
show subpopulations
Gnomad4 AFR exome
AF:
0.0226
Gnomad4 AMR exome
AF:
0.00169
Gnomad4 ASJ exome
AF:
0.00
Gnomad4 EAS exome
AF:
0.00
Gnomad4 SAS exome
AF:
0.00
Gnomad4 FIN exome
AF:
0.00
Gnomad4 NFE exome
AF:
0.0000310
Gnomad4 OTH exome
AF:
0.00144
GnomAD4 genome
AF:
0.00691
AC:
1052
AN:
152270
Hom.:
10
Cov.:
32
AF XY:
0.00655
AC XY:
488
AN XY:
74464
show subpopulations
Gnomad4 AFR
AF:
0.0242
Gnomad4 AMR
AF:
0.00216
Gnomad4 ASJ
AF:
0.00
Gnomad4 EAS
AF:
0.00
Gnomad4 SAS
AF:
0.00
Gnomad4 FIN
AF:
0.00
Gnomad4 NFE
AF:
0.0000441
Gnomad4 OTH
AF:
0.00426
Alfa
AF:
0.000646
Hom.:
0
Bravo
AF:
0.00791
Asia WGS
AF:
0.00202
AC:
7
AN:
3470

ClinVar

Significance: Benign
Submissions summary: Benign:5
Revision: reviewed by expert panel
LINK: link

Submissions by phenotype

not specified Benign:3
Benign, no assertion criteria providedclinical testingClinical Genetics Laboratory, Department of Pathology, Netherlands Cancer Institute-- -
Likely benign, criteria provided, single submitterclinical testingDepartment of Pathology and Laboratory Medicine, Sinai Health SystemOct 25, 2017- -
Benign, no assertion criteria providedclinical testingClinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical Center-- -
Breast-ovarian cancer, familial, susceptibility to, 2 Benign:1
Benign, reviewed by expert panelcurationEvidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA)Jan 12, 2015Class 1 not pathogenic based on frequency >1% in an outbred sampleset. Frequency 0.05 (African), derived from 1000 genomes (2012-04-30). -
not provided Benign:1
Likely benign, criteria provided, single submitterclinical testingGeneDxJan 09, 2021- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs201392123; hg19: chr13-32945368; API